| ²é¿´: 300 | »Ø¸´: 2 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
[×ÊÔ´]
¡¾×ÊÔ´¡¿Cancer: Predictions in lymphoma
|
||
|
The presence of a specific cell type in people with lymphoma is negatively associated with survival, providing a new biomarker with potential clinical applications (Proc. Natl. Acad. Sci. USA 107, 12747¨C12754). Jonathan Irish et al. used single-cell profiling in samples of human follicular lymphoma and found a subset of lymphoma cells with defective B cell antigen receptor (BCR) signaling. Jonathan Irish The more of these cells in each tumor, the shorter the overall subject survival. Moreover, these lymphoma cells increased in number as tumors relapsed after chemotherapy. Interestingly, BCR signaling could be reactivated in the defective cells, indicating that BCR signaling was not altogether absent but somehow suppressed. Mechanistically, tumors with high counts of defective BCR cells had less interleukin-7 signaling in infiltrating T cells, but additional work will be required to understand how these cells emerge and what their downstream effects are. In addition to representing a potential biomarker, the existence of cells with defective BCR signaling may provide new targets against follicular lymphoma.¡ªJCL |
» ²ÂÄãϲ»¶
ϸ°ûʵÑéÀï¸÷ÖÖ RNA תȾ µ½µ×ÔÚ¸ÉÂ
ÒѾÓÐ0È˻ظ´
ʵÑé¸É»õ£¡ÌáÈ¡RNA³¬Ïêϸ²Ù×÷²½Öè
ÒѾÓÐ0È˻ظ´
¼ìÑéҽѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ54È˻ظ´
¿ÆÑÐʵÑé£üLFBËèÇÊȾɫȫ¹¥ÂÔ£¬Ò»ÎĶÁ¶®ËèÇÊȾɫÔÀí¡¢²Ù×÷Óë½á¹ûÅжÁ£¡
ÒѾÓÐ0È˻ظ´
comos-rs
ÒѾÓÐ0È˻ظ´
Ϊʲô»áÕâÑù£¿´¿»¯ºóµÄ¡¸µ°°×¡¹Å¨Ëõºó±ä»ë×ÇÁË£¡
ÒѾÓÐ0È˻ظ´
ϸ°ûʵÑéǰ£¬ÎªÊ²Ã´×ÜÓÐÈËÈÃÄãÏȰÑϸ°û¡°¶öÒ»¶ö¡±£¿
ÒѾÓÐ0È˻ظ´
Ki67ȾɫÔÀí¼°²½Öè
ÒѾÓÐ0È˻ظ´
ʵÑé½âÎö£üWestern BlotÅÜÁ×Ëữµ°°×µÄÄѵã·ÖÎö
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
50½ð±ÒÇóÎÄÏ×£ºParticles, Pretreatment, and Performance in Water Filtration
ÒѾÓÐ12È˻ظ´
¡¾Chemistry Add-in for Word¡¿¡¾Î¢ÈíµÄ»¯Ñ§²å¼þ¡¿
ÒѾÓÐ205È˻ظ´
advances in intelligent and soft computing(AISC) ÏÖÔÚ¼ìË÷µ½¶àÉÙ¾íÁË£¿
ÒѾÓÐ9È˻ظ´
һƪÎÄÕÂÒѾ¿ìÁ½ÄêÁË»¹Ã»ÓÐdecision£¬automation in construction ÄãÊÇÔõôÁË£¿
ÒѾÓÐ13È˻ظ´
Panda in the breeding center in Chengdu
ÒѾÓÐ9È˻ظ´
Çë½Ì¸÷λ´óÏÀÎÞÍø¸ñGalerkin·¨¿ÉÒÔÓÃÀ´Çó½â¸ß½×µÄƫ΢·Ö·½³ÌÂð£¿
ÒѾÓÐ5È˻ظ´
technical check in progress 12ÌìÁË£¡£¡£¡
ÒѾÓÐ6È˻ظ´
Structural Analysis: In Theory and Practice
ÒѾÓÐ56È˻ظ´
My second diary in the English Cafe
ÒѾÓÐ4È˻ظ´
Tell me a joke in English
ÒѾÓÐ9È˻ظ´
ÇóÖú£ºAnti-Cancer Agents in Medicinal ChemistryÔÓÖ¾µÄÒªÇó¼°¸ñʽ¡£
ÒѾÓÐ5È˻ظ´
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer
ÒѾÓÐ2È˻ظ´
ISIF Journal of Advances in Information FusionÊÇ·ñ±»SCI¼ìË÷£¿
ÒѾÓÐ4È˻ظ´
moderate revise Ö®ºó2Ìì±ä³ÉDecision in Process½ÓÊյļ¸ÂÊ´óÂð
ÒѾÓÐ74È˻ظ´
lrj107hn
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 0.844
- ½ð±Ò: 5111.9
- Ìû×Ó: 1219
- ÔÚÏß: 316.6Сʱ
- ³æºÅ: 86279
3Â¥2010-09-14 18:17:29
|
°©Ö¢£ºÁܰÍÁöÖеÄÔ¤²âÒò×Ó ÁܰÍÁö²¡ÈËÖÐÌØÒìϸ°ûÀàÐ͵ĴæÔÚÓ벡È˵ÄÉú´æ³Ê¸ºÏà¹Ø£¬¸Ã·¢ÏÖ¿ÉÌṩһÖÖеÄÉúÎï±ê¼ÇÎ²¢¾ßÓÐDZÔÚµÄÁÙ´²ÒâÒå¡£ ÔÚÂËÅÝÐÔÁܰÍÁöÑù±¾ÖÐʹÓõ¥Ï¸°û·ÂÐÎÇÐÏ÷¼¼Êõ·¢ÏÖÁËһЩ¾ßÓÐȱÏÝBϸ°û¿¹ÔÊÜÌ壨BCR£©ÐźŵÄÁܰÍÁöϸ°û¡£Ã¿¸öÖ×ÁöÖÐÕâЩϸ°ûÔ½¶à£¬²¡È˵ÄÉú´æÆÚÔ½¶Ì¡£¶øÇÒ£¬µ±»¯ÁƺóÖ×Áö¸´·¢Ê±ÕâЩÁܰÍÁöϸ°ûÊýÁ¿ÉÏÔö¼Ó¡£ÁîÈ˸ÐÐËȤµÄÊÇ£¬ÔÚÕâЩȱÏÝϸ°ûÖÐBCRÐźſÉÄÜÖØÐ»£¬ÌáʾBCRÐźŲ»ÊÇÒ»Æðȱ·¦¶øÊÇÓÐЩ±»ÒÖÖÆÁË¡£ »úÖÆÉÏ£¬°éÓнϸßÊýÁ¿È±ÏÝBCRµÄÖ×ÁöÔÚ½þÈóµÄTϸ°ûÖнÏÉÙ±í´ïIL-7Ðźţ¬µ«ÐèÒªÁíÍâµÄ¹¤×÷À´Àí½âÕâЩϸ°ûÊÇÈçºÎ³öÏֵĺÍËüÃǵÄÏÂÓÎЧӦÊÇʲô¡£ ³ýÁË´ú±íDZÔÚµÄÉúÎï±ê¼ÇÎïÍ⣬°éÓÐȱÏÝBCRÐźŵÄϸ°û´æÔÚ¿ÉÌṩÂËÅÝÐÔÁܰÍÁöеİе㡣 |
2Â¥2010-09-14 16:35:17













»Ø¸´´ËÂ¥